Our services

ADC Review
is made possible by:




PEER-REVIEWED ARTICLES

Study Shows Concentration of Intratumoral Payload Correlates with ADC Activity

A study published in the March 2018 edition of Molecular Cancer Therapeutics shows that, while antibody–drug conjugates or ADC have become important scaffolds for targeted cancer therapies, ADC exposure–response correlation is not well characterized.[1]

Donglu Zhang, Shang-Fan Yu, Cyrus Khojasteh and their other colleagues at Genentech have demonstrated that intratumor payload exposures correlated well with the corresponding efficacies of several disulfide-linked ADCs, bearing an DNA alkylating agent, pyrrolo[2,1-c][1,4]benzodiazepine-dimer or PBD, in HER2-expressing xenograft models.

“Plateau” effect
The correlation suggests that a threshold concentration of intratumor payload is required to support sustained efficacy and an antibody-drug conjugate can deliver an excessive level of payload to tumors that does not enhance efficacy – which may be referred to a the “Plateau” effect.

In contrast to tumor PBD concentrations, related assessments of systemic exposures, plasma stability, and drug-to-antibody ratio or DAR changes of related ADCs did not consistently rationalize the observed ADC efficacies.

Minimal efficacious dose
A minimal efficacious dose could be determined by ADC dose-fractionation studies in the xenograft models. Mechanistic investigations revealed that both linker immolation and linker disulfide stability are the key factors that determine intratumor PBD concentrations.

The results of the study clearly demonstrates how a linker design can impact ADC efficacy and that the intratumor exposure of a payload drug as the molecular mechanism quantitatively correlate with and predict the antitumor efficacy of antibody-drug conjugates.


Last editorial review: March 1, 2018

Featured Image: Laboratory test tube. Scientific research background. Courtesy: © 2010 – 2018 Fotolia. Used with Permission.

Copyright © 2010 – 2018 InPress Media Group, LLC. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Share

IMGN779 Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML Cells

CD33 is broadly expressed on leukemic blasts of patients with acute myeloid leukemia. [1] Although nearly 80% of patients show a high initial response rates to chemotherapy, many patients with acute myeloid leukemia (AML) experience a relapse of the disease due to the outgrowth of persistent leukemic stem cells or LSC. Researchers have found that the differential expression of CD33 on leukemic stem cells compared to normal hematopoietic stem cells (HSC) makes CD33 attractive as a target for treatment of acute myeloid leukemia.[1][2]

Data presented during the 57th American Society of Hematology (ASH) Annual Meeting and Exposition which took place in Orlando, Florida, December 5-8, 2015, shows that IMGN779, a novel, experimental, CD33-targeting antibody-drug conjugate utilizing the humanized antibody Z4681A conjugated to DGN462, a novel DNA-alkylating agent consisting of an indolino-benzodiazepine dimer containing a mono-imine moiety, through a cleavable disulfide linker, sulfo-SPDB, is expected to make a meaningful potential in the treatment of patients with acute myeloid leukemia (AML). The novel ADC is being developed by ImmunoGen, Inc., Waltham, MA. [3]

Photo: Exhibition hall. 57th American Society of Hematology (ASH) Annual Meeting and Exposition which took place in Orlando, Florida, December 5-8, 2015.

While most cases of acute myeloid leukemia, also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia, develop from cells that turn into white blood cells (other than lymphocytes), some cases develop in other types of blood-forming cells.

Staring in the bone marrow, AML, in most cases, quickly moves into the blood and,  sometimes, spread to other parts of the body including the lymph nodes, liver, spleen, central nervous system (including brain and spinal cord), and testicles. [4]

Key statistics
Acute myeloid leukemia, which is slightly more common among men than among women, is generally a disease of older people and is uncommon before the age of 45. The average age of a patient with AML is about 67 years. In 2015 in the United States, according to the American Cancer Society, about 20,830 new cases of acute myeloid leukemia have been diagnosed. Most of them in adults. Furthermore, about 10,460 died from AML. [4]

In people younger than 60 years of age, treatment of AML is fairly standard, involving cycles of intensive chemotherapy including cytarabine (cytosine arabinoside or ara-C) and the anthracycline drugs (such as daunorubicin (daunomycin), idarubicin, and mitoxantrone). This may, sometimes, go along with a stem cell transplant. However, in patients older than 60 years of age, this may be different. If older patients are healthy enough to be treated in the same way, the chemotherapy may be less intense. However, people who are much older or who are in poor health may not be able to tolerate this intense treatment, creating a large unmet need. [4] Novel, targeted therapies may be able address this need.

Meaningful difference
Study results presented this year, show how researchers investigated the mechanism of action of DGN462 and IMGN779, using AML cell lines and primary patient AML samples to evaluate DNA binding, DNA alkylation versus cross-linking, cell cycle effects and DNA damage signaling, apoptosis, and cell death.

The results suggest that cell killing by DGN462 and IMGN779 are highly potent against AML cell lines in vitro and in primary patient AML samples, acting mechanistically via induction of DNA damage, which is accompanied by cell cycle arrest, leading to apoptosis.

In this study researchers induced phosphorylated H2AX (a marker of DNA damage) and cleaved Caspase-3 (a markers of apoptosis), in a time dependent manner following exposure to either DGN462 or IMGN779.

Based on the results, IMGN779 is advancing to clinical testing for the treatment of relapsed and/or refractory CD33+ acute myeloid leukemia. In new pharmacodynamic studies, utilizing phosphorylated H2AX as a biomarker, researchers expect to verify the mechanism of DGN462, a novel DNA alkylating payload which covalently binds to cellular DNA, without cross-linking.

“The IMGN779 data being reported relate to its novel mechanism of action, which we believe could help patients with acute myeloid leukemia, and we expect to start clinical testing of this experimental therapy in early 2016,” noted Charles Morris, MBChB, MRCP, ImmunoGen’s Executive Vice President and Chief Development Officer.

Preclinical data was previously presented during the 2014 annual meeting of the American Society of Hematology. [5][6]

“We believe the unique profile of IMGN779 will enable [us to] achieve a desired activity with a better tolerability profile than other agents currently used to treat this disease,” Morris concluded.


Last Editorial Review: December 12, 2015

Photo: Exhibition hall during the 57th Annual Meeting of the American Society of Hematology. Courtesy: © Sunvalley Communication, LLC. Used with permission.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Skip to toolbar